Clinical Trials Logo

Oncology Patients clinical trials

View clinical trials related to Oncology Patients.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02110355 Completed - Cancer Clinical Trials

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

Start date: December 19, 2014
Phase: Phase 1
Study type: Interventional

Phase 1b/2a, open-label, sequential dose escalation and expansion study of AMG 232 in combination with trametinib and dabrafenib in subjects with metastatic melanoma followed by a direct comparison of AMG 232 combined with trametinib and dabrafenib versus trametinib combined with dabrafenib alone.

NCT ID: NCT02016729 Completed - Cancer Clinical Trials

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

Start date: April 1, 2014
Phase: Phase 1
Study type: Interventional

Open-label, sequential dose escalation and expansion study of AMG 232 in subjects with acute myeloid leukemia.

NCT ID: NCT01723020 Completed - Cancer Clinical Trials

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

Start date: December 27, 2012
Phase: Phase 1
Study type: Interventional

First in human, open-label, sequential dose escalation and expansion study of AMG 232 in subjects with advanced solid tumors or multiple myeloma

NCT ID: NCT01444404 Completed - Cancer Clinical Trials

A Study of AMG 820 in Subjects With Advanced Solid Tumors

Start date: March 31, 2008
Phase: Phase 1
Study type: Interventional

First in human, open-label, sequential dose escalation and expansion study of AMG 820 in subjects with advanced solid tumors.

NCT ID: NCT01300026 Completed - Cancer Clinical Trials

AMG 319 Lymphoid Malignancy FIH

Start date: April 2011
Phase: Phase 1
Study type: Interventional

This is a multi-center, phase 1, open-label first-in-human study of AMG 319 in subjects with relapsed or refractory lymphoid malignancies. This study consists of two parts. The dose exploration in part 1, studies cohorts of 3 subjects with relapsed or refractory lymphoid malignancies and uses a practical continuous reassessment model [CRM] to guide dose escalation and to define the MTD. The dose expansion in part 2 will enroll 20 subjects with CLL at a dose no higher than the MTD and further explore the safety, PK, and clinical activity of AMG 319 in this patient population.

NCT ID: NCT01253707 Completed - Cancer Clinical Trials

A Study of AMG 337 in Subjects With Advanced Solid Tumors

Start date: December 8, 2010
Phase: Phase 1
Study type: Interventional

First in human, open-label, sequential dose escalation and expansion study of AMG 337 in subjects with advanced solid tumors.

NCT ID: NCT00813384 Completed - Cancer Clinical Trials

A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors

Start date: December 2008
Phase: Phase 1
Study type: Interventional

First in human, open-label, sequential dose escalation and expansion study of AMG 208 in subjects with advanced solid tumors.